Analyst projections of slower revenue growth for Cooper Companies (COO), along with past growth projects that did not clear the healthcare sector’s cost of capital, have put the stock’s recent underperformance in sharper focus for investors. See our latest analysis for Cooper Companies. Over the past year Cooper Companies has seen some recovery in its share price, with a 90 day share price return of 21.76% and a 1 year total shareholder return of 1.25%. However, the 3 year and 5 year total...

In recent months, CooperCompanies has faced a softer outlook as analysts now expect its revenue to grow more slowly than in prior years, pointing to potential demand challenges. An important underlying issue is that past growth investments have generated returns below the healthcare industry’s cost of capital, raising fresh questions about how efficiently management is deploying capital. Next, we’ll examine how this weaker revenue growth outlook and capital efficiency concern could reshape...

Cooper Companies stock has delivered a decline of 31.3% over the past five years, yet the current valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to attractive upside while earnings based multiples suggest the shares are on the expensive side. Over five years, Cooper Companies has fallen 31.3%, which means long term holders are still under water even after more recent gains. The key support for the current valuation is the market's confidence...

Over the last six months, CooperCompanies’s shares have sunk to $75.74, producing a disappointing 9.5% loss - a stark contrast to the S&P 500’s 12.9% gain. This may have investors wondering how to approach the situation.

Cooper Companies' 22% three-month surge reflects contact lens share gains, MiSight growth and a recovering fertility business.

Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

HeartFlow (HTFL) delivered earnings and revenue surprises of +50.00% and +12.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cooper Companies' premium lens migration, MiSight growth and fertility recovery offer long-term upside despite Asia-Pacific, tariff and FX pressures.

Staar Surgical (STAA) delivered earnings and revenue surprises of +47.62% and +3.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

COO vs. MMSI: Which Stock Is the Better Value Option?

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Cooper Companies' share price has fallen about 33% over the past five years, and with the stock now around US$70.31, the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the past five years, Cooper Companies has delivered a cumulative shareholder loss of roughly 33%, which raises the bar for the current price to be supported by future earnings and cash flows. For long term valuation, the key support may come from Cooper Companies'...

The Cooper Companies is set to report Q3 earnings, with analysts expecting a marginal year-over-year EPS growth.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Cooper Companies' premium contact lenses, restructuring gains and product launches support growth despite regional and competitive headwinds.